Status:
COMPLETED
Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)
Lead Sponsor:
Joint Authority for Päijät-Häme Social and Health Care
Conditions:
Multiple Actinic Keratoses
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of the study is to compare the efficacy of two photosensitizers, methyl-aminolaevulinate (MAL) and 5-aminolaevulinic nanoemulsion (BF-200 ALA) in the treatment of facial actinic keratosis. We ...
Detailed Description
Actinic keratoses (AKs) are superficial premalignant skin lesions that can progress into an invasive or metastatic squamous cell carcinoma. AKs can be treated with photodynamic therapy (PDT), of which...
Eligibility Criteria
Inclusion
- actinic keratoses symmetrically on face or scalp
- age over 18 years
- there must be at minumum one ak sized 6mm2 symmetrically on both sides
- patients must be able to make the decision to attend independently
Exclusion
- pregnancy
- lactation
- lack of compliance
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01893203
Start Date
August 1 2013
End Date
December 1 2014
Last Update
July 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Päijät-Häme Central Hospital
Lahti, Finland, 15850